Introduction {#Sec1}
============

Atherosclerotic coronary artery disease (CAD) remains the leading cause of morbidity and mortality in the USA, and accordingly, approximately 1,350,000 patients suffer an acute coronary syndrome (ACS) each year \[[@CR1]\]. Moreover, approximately 20 % of patients who suffered an initial event will have a recurrent event within a year \[[@CR2], [@CR3]\].

Atherosclerosis progresses through a series of molecular and cellular processes resulting in a series of geometrical and compositional changes that can be detected by imaging modalities \[[@CR4]\]. The "vulnerable plaque" paradigm hypothesizes that certain histopathological features of coronary atherosclerotic plaques are associated with plaque rupture \[[@CR5]\] and include mild--moderate luminal stenosis, large plaque burden, more lipid pool and lipid-rich necrotic core, more inflammation, and less calcification. Moreover, thin-cap fibroatheromas (TCFA) are the most predominant morphology found in autopsy series of ruptured plaques \[[@CR6]--[@CR13]\]. However, prospective validation of such features in vivo has been challenging in the absence of a reliable imaging method.

Recently, gray-scale intravascular ultrasound (IVUS) and IVUS with radiofrequency backscatter analysis (IVUS/VH) have been utilized as an invasive means of visualizing human coronary arterial plaques in vivo \[[@CR14]\]. Several retrospective IVUS/VH studies demonstrated that plaques associated with events had larger plaque burden, more necrotic core, less calcification, and the presence of IVUS/VH defined TCFA (VH-TCFA) \[[@CR15]\]. Furthermore, a recent, large, prospective study (PROSPECT: "A prospective natural-history study of coronary atherosclerosis") utilizing three-vessel IVUS/VH based on cross-sectional luminal analysis showed that minimal lumen area (MLA) plaque burden and the presence of VH-TCFA were independent predictors of major adverse cardiovascular events (MACE) \[[@CR16]\]. However, features of non-obstructive plaques that resulted in MACE prospectively over a 12-month period have not been investigated before in three-dimension (3D) on a per-plaque basis. Accordingly, we hypothesized that plaques associated with MACE over a 12-month period will have larger plaque burden, more non-calcified plaque, more necrotic core, and less dense calcium compared to lesions that were not associated with MACE, based on 3D IVUS/VH measurements on a per-plaque basis.

Methods {#Sec2}
=======

General Study Design {#Sec3}
--------------------

The ATLANTA (Assessment of Tissue characteristics, Lesion morphology and hemodynamics by Angiography with fractional flow reserve, intravascular ultrasound and virtual histology and Non-invasive computed Tomography in Atherosclerotic plaques) study was a prospective, single-center, investigator-initiated study approved by the Institutional Review Board of Piedmont Healthcare. The overall study design has been published previously \[[@CR15]\] and is shown in Fig. [1](#Fig1){ref-type="fig"}. Patients with intermediate coronary arterial lesions who presented with signs or symptoms suggestive of myocardial ischemia and who qualified for the study based on enrollment criteria were included either from the cardiac catheterization laboratory or from the cardiovascular computed tomography laboratory. Main inclusion criteria included the following: adults ages 18--70, no known or prior CAD, symptoms suggestive of myocardial ischemia or high likelihood of CAD, and at least one "intermediate" coronary lesion (40--70 % percent diameter stenosis based on CTA or XRA). All patients underwent invasive coronary angiography (XRA) with quantitative coronary angiography (QCA), fractional flow reserve (FFR) measurements, intravascular ultrasound (IVUS) with radiofrequency backscatter analysis (IVUS/VH), and multi-detector computed tomography (MDCT) coronary angiography (CTA) at baseline. A "study lesion" was prospectively identified in each patient, which was quantitatively evaluated by CTA, IVUS/VH, and FFR measurements. Patients were contacted 6 and 12 months after the baseline evaluation for follow-up and returned at 1 year for repeat CTA examination. The 6- and 12-month follow-up visits were conducted through telephone interviews.Fig. 1ATLANTA study design. Patients with intermediate lesions (40--70 %) were recruited based on XRA or CTA; each pre-specified study lesion underwent IVUS/VH and FFR. CTA was repeated at 12 months. *CTA* computed tomography angiography, *XRA* invasive X-ray coronary angiography, *QCA* quantitative coronary angiography, *FFR* fractional flow reserve, *IVUS* intravascular ultrasound, *VH* virtual histology

Study Endpoints, Event Definitions, and Adjudication Process {#Sec4}
------------------------------------------------------------

The primary endpoint of the overall study was an agreement between CTA and IVUS/VH for quantitative measurements of coronary plaque and stenosis and has been published elsewhere \[[@CR15]\]. Therefore, sample size calculation was predicated on the number of patients required to assess the agreement between CTA- and IVUS/VH-derived quantitative measurements of plaque. Although the study was not powered to predict cardiovascular events, we prospectively collected MACE in a pre-specified manner. Pre-specified components of MACE included death from any cause, myocardial infarction (MI), target lesion revascularization (TLR), and ischemia distal to the study lesion, in a hierarchal fashion. For example, if a patient had ischemia in the territory of the study lesion that resulted in TLR, this event was only accounted for as TLR and not as TLR and ischemia. MI was defined using standard AHA/ACC definitions and included both ST-segment elevation and non-ST-segment elevation MI \[[@CR17]\]. TLR was defined as either percutaneous coronary intervention (PCI) of the study lesion or coronary artery bypass grafting (CABG) that bypassed the study lesion. Myocardial ischemia was defined as reversible perfusion defect on radionuclide myocardial perfusion imaging, vasodilator stress cardiovascular magnetic resonance examination, or stress-induced wall motion abnormality on stress echocardiography. The AHA/ASNC 17-segment model was used to assign myocardial territories to each study lesion \[[@CR18]\].

Each component of MACE was carefully assessed during the 6- and 12-month interviews with patients using a prospectively designed, structured questionnaire, addressing each component of the pre-specified MACE endpoint. In addition, all hospitalization records, cardiovascular procedural records, and interim office-visit records were reviewed to ensure adequate follow-up information. All cardiac catheterization images were reviewed in patients who underwent PCI or CABG during the follow-up to determine whether the study lesion was indeed revascularized. Patients who could not be contacted and who did not respond were checked against the Social Security Death Index (SSDI).

Once all information regarding cardiovascular outcomes was collected, each prospective event was carefully adjudicated by two cardiologists independently (S.V. and S.R.), and disagreement was resolved by consensus.

IVUS-VH Image Acquisition {#Sec5}
-------------------------

After intracoronary injection of nitroglycerin (mean total dose per case, 561.5 mcg; range, 0--1,800 mcg) and after placing a guiding catheter in the target coronary artery, a 3.2-F, 20-mHz ultrasound catheter (Eagle Eye; Volcano Inc.; Rancho Cordova, CA, USA) was inserted and was advanced at least 2 cm beyond the most distal portion of the target lesion. Automated pullback was performed at a rate of 0.5 mm/s (R-100; Volcano Inc.; Rancho Cordova, CA, USA). The electrocardiographic signal was simultaneously recorded for the reconstruction of the radiofrequency backscatter information using In-Vision Gold (Volcano Inc.; Rancho Cordova, CA, USA).

IVUS/VH Image Analysis {#Sec6}
----------------------

De-identified IVUS/VH datasets were analyzed by an experienced cardiologist (G.V.) using dedicated software (pcVH 3.0.394, Volcano Inc., Rancho Cordova, CA, USA) on a dedicated workstation. Semi-automatic contouring of the luminal boundary and the external elastic lamina was performed in each frame. For plaque geometrical parameters, plaque burden was calculated as the difference between the vessel area and the luminal area expressed as a percentage of the vessel area (Fig. [2](#Fig2){ref-type="fig"}). Based on a previously validated algorithm \[[@CR14]\], the software classified each pixel as dense calcium (DC; white color), fibrous tissue (FI; green color), fibrofatty tissue (FF; light green color), and necrotic core (NC; red color; Fig. [3](#Fig3){ref-type="fig"}). Total volume and percentage of each of the four components was measured in the study segment. Furthermore, we calculated the volume and percent of all non-calcified plaque components (sum of NC, FF, and FI).Fig. 2The figure represents the schematic for calculation of plaque burden for 2D study segment. *2D* bi-dimensional, *EEL* external elastic lamina, *IEL* internal elastic lamina, *V* vessel area, *L* lumen areaFig. 3Plaque composition by intravascular ultrasound with radiofrequency backscatter analysis (IVUS/VH). IVUS/VH segment is shown in the entire longitudinal section (**a**) and in cross-section at the minimal luminal area (MLA) frame (**b**)

Each study lesion was evaluated both in a two-dimensional (2D) and 3D fashion. Plaque classification was performed based on the plaque composition and geometrical analysis by IVUS/VH. Each plaque was characterized based on accepted IVUS/VH phenotypes such as pathological intimal thickening (PIT), thick-cap fibroatheroma (ThCFA), and TCFA \[[@CR14], [@CR19]\]. PIT was defined as the presence of predominantly FI and FF tissue with ≤10 % of NC, ≤10 % of DC, and with a plaque burden ≥40 % in three consecutive frames. Fibroatheroma lesion was determined by a plaque burden ≥40 % with a NC ≥10 % in three consecutive frames. The fibroatheroma lesions were classified based on the presence (VH-ThCFA) or absence (VH-TCFA) of a fibrous cap (Fig. [4a--c](#Fig4){ref-type="fig"}).Fig. 4Morphological lesion subtypes identified by intravascular ultrasound with radiofrequency backscatter analysis (IVUS/VH). Three plaque subtypes are shown: (**a**) pathological intimal thickening (PIT), (**b**) thick-cap fibroatheroma (VH-ThCFA), and (**c**) thin-cap fibroatheroma (VH-TCFA)

### 2D analysis {#d30e538}

2D analysis was predicated on the site of the minimal luminal area (MLA). Plaque geometrical parameters \[minimal luminal diameter (MLD), MLA, and plaque burden\] were measured in the MLA frame, as well as in a frame proximal and distal to the MLA, and values from these three consecutive frames were averaged. Similarly, area and percentage of each plaque component was measured in the same three consecutive frames and were averaged between these frames (Fig. [5a](#Fig5){ref-type="fig"}).Fig. 5Schematic representation of 2D and 3D IVUS/VH analysis. For the 2D-IVUS/VH analysis, plaque geometrical parameters (MLD, MLA, and plaque burden) were measured in the MLA frame as well as in a frame proximal and distal to the MLA, and the values from these three consecutive frames were averaged (**a**). For the 3D-IVUS/VH analysis, in each subject, the entire vessel pullback from the IVUS/VH dataset was analyzed frame-by-frame, and the MLA frame was identified. The study segment was extended proximally and distally from the MLA frame until three consecutive frames had less than 40 % plaque burden (**b**). *2D* bi-dimensional, *3D* three-dimensional, *IVUS* intravascular ultrasound, *VH* virtual histology, *MLA* minimal lumen area

### 3D analysis {#d30e577}

In addition to the 2D analysis, we also measured plaque geometrical and compositional parameters in each distinct plaque within the region of the entire IVUS/VH pullback. The entire vessel pullback from the IVUS/VH dataset was analyzed frame-by-frame in each subject, and the MLA frame was identified. The study segment was extended proximally and distally from the MLA frame until three consecutive frames had less than 40 % plaque burden (Fig. [5b](#Fig5){ref-type="fig"}). Absolute total plaque volume was measured in each plaque, as well as the volume and percent of each of the four plaque components. Plaque burden was also calculated in 3D in the entire plaque as the difference between the vessel volume and the luminal volume expressed as a percentage of the vessel volume.

Statistical Methods {#Sec7}
-------------------

Normally distributed continuous variables are expressed as mean ± SD, and non-normally distributed variables as median (inter-quartile range). Normality of distribution was assessed by the Kolmogorov--Smirnoff test. Clinical features and IVUS/VH-derived plaque geometrical and compositional parameters were compared between patients with and without MACE using two-sided, unpaired Student\'s *t* test for variables with normal distribution, with Kruskal--Wallis one-way analysis of variance for non-normally distributed variables and with the Fischer exact test for categorical data sets. A *p* value of 0.05 or less was considered statistically significant. Variables that were significant in univariate analysis were entered in a multivariable stepwise logistic regression model.

Results {#Sec8}
=======

General Demographics {#Sec9}
--------------------

Sixty patients were enrolled in the study; general demographic characteristics are shown in Table [1](#Tab1){ref-type="table"}. Mean age was 60.4 ± 7.2 years, and 60 % were men. Mean 10-year Framingham risk score in the study population was 8.4 ± 6.0 %. The presence of hypertension, diabetes, dyslipidemia, tobacco use, and lipoprotein levels were representative for a population with no prior CAD presenting with signs and symptoms of myocardial ischemia (Table [1](#Tab1){ref-type="table"}).Table 1Baseline clinical characteristicsCharacteristicAll (*N* = 60)MACE (*N* = 5)No MACE (*N* = 55)*p* valueAge (years)60.4 ± 7.258.4 ± 6.660.6 ± 7.30.5Men, %60 %60 %60 %1Ethnicity  Caucasians92 %100 %91 %1  African-Americans8 %0 %9 %Risk factors  Hypertension83 %80 %84 %1  Dyslipidemia95 %100 %95 %1  Tobacco use58 %60 %58 %1  Diabetes73 %80 %73 %1Framingham risk score (10-year risk)8.5 ± 6.010.2 ± 9.98.3 ± 5.60.5Symptoms  Chest pain45 %60 %44 %1  Shortness of breath10 %0 %11 %1Medications  Aspirin71 %100 %69 %0.3  Beta-blockers51 %40 %52 %0.7  ACE inhibitor31 %40 %30 %0.6  ARB10 %20 %9 %0.4  Nitrate10 %40 %7 %0.08  Statin68 %40 %70 %0.3  Cholesterol absorption   inhibitors25 %0 %28 %0.3  Niacin15 %20 %15 %0.6  Fibric acid derivatives5 %0 %6 %1Normally distribute variables, mean ± SD*MACE* major adverse cardiac events, *SD* standard deviation

Major Adverse Cardiovascular Events (MACE) {#Sec10}
------------------------------------------

At the end of the pre-specified 12-month follow-up, a total of five patients (8.3 %) had an adjudicated MACE. The five patients in the MACE group presented with unstable angina. There was no death or myocardial infarction. All the five MACE were in the form of target lesion revascularization; four patients (6.7 %) had PCI, and one patient (1.7 %) had CABG. Median time to event was 72 days. IVUS/VH data was not available in one patient in the MACE group.

Clinical Parameters and FFR {#Sec11}
---------------------------

The MACE and the no-MACE groups were similar with respect to age, presence of hypertension, diabetes, dyslipidemia, and tobacco use. Lipoprotein parameters were also similar between the groups (Table [2](#Tab2){ref-type="table"}). Lesions associated with MACE were non-flow-limiting and were not different from lesions with no MACE; mean FFR in the no-MACE group was 0.89 and in the MACE group was 0.90 (*p* = 0.7).Table 2Baseline lipoprotein valuesCharacteristicAll (*N* = 60)MACE (*N* = 5)No MACE (*N* = 55)*p* valueLaboratory valuesTC (mg/dL)155.0 ± 43.3166.0 ± 14.9154.0 ± 45.00.6ApoB (mg/dl)78.1 ± 27.586.8 ± 15.477.3 ± 28.40.5LDL-C (mg/dl)84.7 ± 35.797.1 ± 19.483.5 ± 36.70.4ApoAI (mg/dl)144.9 ± 30.1154.5 ± 35.6144.0 ± 29.80.5HDL-C38.3 ± 12.139.2 ± 10.938.2 ± 12.60.9Normally distribute variables, mean ± SD

IVUS/VH Parameters in the Overall Population {#Sec12}
--------------------------------------------

### IVUS/VH Parameters: 2D Analysis {#Sec13}

#### Geometry {#d30e1151}

Geometrical parameters \[MLD, MLA, percentage of area stenosis (%AS), and percentage of diameter stenosis (%DS)\] were not different between the groups by IVUS/VH analysis (Table [3](#Tab3){ref-type="table"}).Table 32D IVUS/VH geometrical plaque differences between MACE and no MACE groupsIVUS/VH parameterMACE (mean ± SD)No MACE (mean ± SD)*p* valueMLD1.78 ± 0.461.96 ± 0.480.5MLA3.62 ± 1.524.12 ± 2.120.6%AS46.8 ± 22.452.7 ± 15.80.5%DS26.0 ± 20.2931.6 ± 11.520.4Normally distribute variables, mean ± SD*IVUS* intravascular ultrasound, *VH* virtual histology, *MLD* minimal lumen diameter, *MLA* minimal lumen area, %*AS* percentage area stenosis, %*DS* percentage diameter stenosis, *MACE* major adverse cardiac events, *SD* standard deviation

#### Composition {#d30e1271}

2D analysis showed significantly higher plaque area in lesions associated with MACE compared to those without MACE (12.5 ± 8.3 vs. 7.9 ± 3.5 mm^2^, *p* = 0.04). DC percentage was lower in the MACE group (2.5 ± 0.3 % vs. 13.4 ± 9.4 %, *p* = 0.03), while FF area and percentage were higher (2.9 ± 1.7 vs. 0.8 ± 1.0 mm^2^, *p* \< 0.001, and 34.2 ± 15.9 % vs. 12.5 ± 10.2 %, *p* \< 0.001, respectively). Other compositional parameters were comparable in the two groups (Table [4](#Tab4){ref-type="table"} and Fig. [6](#Fig6){ref-type="fig"}). Plaque type was characterized as VH-TCFA in all five patients with MACE, while only 32 of 47 patients (69 %) in the no-MACE group had this lesion type (*p* = 0.42). Other lesion subtypes in the no-MACE group were VH-ThCFA (29 %) and PIT (2 %).Table 42D IVUS/VH compositional plaque differences between MACE and no MACE groupsIVUS/VH parameterMACE (mean ± SD)No MACE (mean ± SD)*p* valuePlaque area12.5 ± 8.37.9 ± 3.50.04FI area4.8 ± 4.22.7 ± 1.70.5FF area2.9 ± 1.70.8 ± 0.9\<0.001NC area1.7 ± 1.91.3 ± 1.00.5DC area0.2 ± 0.20.7 ± 0.60.2FI, %47.9 ± 7.051.1 ± 13.90.7FF, %34.2 ± 15.912.5 ± 10.2\<0.001NC, %15.4 ± 9.323.0 ± 10.50.2DC, %2.5 ± 0.313.4 ± 9.40.03Normally distribute variables, mean ± SD*2D* bi-dimensional, *IVUS* intravascular ultrasound, *VH* virtual histology, *MACE* major adverse cardiac events, *SD* standard deviation, *FI* fibrous, *FF* fibrofatty, *NC* necrotic core, *DC* dense calciumFig. 6Significant predictors of MACE via the two-dimensional (2D; *top row*) and three-dimensional (3D; *bottom row*) IVUS/VH analyses. *MACE* major adverse cardiac events, *2D* bi-dimensional, *3D* three-dimensional, *IVUS* intravascular ultrasound, *VH* virtual histology

### IVUS/VH Parameters: 3D Analysis {#Sec14}

#### Geometry {#d30e1518}

There were no differences in MLD and MLA by IVUS/VH between the MACE and no-MACE groups (Table [5](#Tab5){ref-type="table"}).Table 53D IVUS/VH geometrical plaque differences between MACE and no MACE groupsIVUS/VH parameterMACE (mean ± SD)No MACE (mean ± SD)*p* valueMLD1.78 ± 0.461.96 ± 0.480.5MLA3.62 ± 1.524.12 ± 2.120.6%AS46.8 ± 22.452.7 ± 15.80.5%DS26.0 ± 20.2931.6 ± 11.520.4RI88.0 ± 1.888.6 ± 9.90.9Normally distribute variables, mean ± SD*3D* three-dimensional, *IVUS* intravascular ultrasound, *VH* virtual histology, *MLD* minimal lumen diameter, *MLA* minimal lumen area, %*AS* percentage area stenosis, %*DS* percentage diameter stenosis, *MACE* major adverse cardiac events, *RI* remodeling index, *SD* standard deviation

#### Composition {#d30e1657}

Lesions associated with MACE had significantly larger plaque burden as compared to lesions not associated with MACE (65.1 ± 5.1 % vs. 53.0 ± 7.8 %, *p* = 0.004). FF volume and percentage were significantly higher in the MACE group as compared to the no-MACE group (44.1 ± 30.3 vs. 20.7 ± 15.9 mm^3^, *p* = 0.01, and 17.6 ± 12.7 % vs. 10.0 ± 5.6 %, *p* = 0.02, respectively). The MACE group had a proportionally higher amount of non-calcified plaque (NCP; 93.6 ± 3.5 % vs. 86.0 ± 7.8 %, *p* = 0.05). Conversely, the percentage of DC was lower in MACE-associated lesions (6.4 ± 3.5 % vs. 14.0 ± 7.8 %, *p* = 0.05). Results are shown in Table [6](#Tab6){ref-type="table"} and illustrated in Fig. [6](#Fig6){ref-type="fig"} (bottom row).Table 63D IVUS/VH compositional plaque differences between MACE and no MACE groupsIVUS/VH parameterMACE (mean ± SD)No MACE (mean ± SD)*p* valuePlaque burden (%)65.1 ± 5.153.0 ± 7.80.004FI volume133.0 ± 74.0106.0 ± 70.60.5FF volume44.1 ± 30.320.7 ± 15.90.01NC volume51.8 ± 32.154.2 ± 36.00.9DC volume17.3 ± 14.231.0 ± 27.50.3FI, %54.6 ± 8.151.0 ± 10.00.5FF, %17.6 ± 12.710.0 ± 5.60.02NC, %21.3 ± 7.125.0 ± 6.50.3DC, %6.4 ± 3.514.0 ± 7.80.05NCP, %93.6 ± 3.586.0 ± 7.80.05All volumes are in cubic millimeters*3D* three-dimensional, *IVUS* intravascular ultrasound, *VH* virtual histology, *MACE* major adverse cardiac events, *SD* standard deviation, *FI* fibrous, *FF* fibrofatty, *NC* necrotic core, *DC* dense calcium, *NCP* non-calcified plaque

Multivariable Analysis {#Sec15}
----------------------

Clinical features and IVUS-VH plaque characteristics were tested in a multivariable stepwise logistic regression model that included age, gender, presence of diabetes, lipoprotein parameters, and the geometrical and compositional plaque parameters as independent variables and MACE as the dependent variable. Only fibrofatty volume was retained as an independent variable with an odds ratio of 1.058 for MACE (95 % confidence interval, 1.004 to 1.115, *p* = 0.03).

Discussion {#Sec16}
==========

There are two significant novel aspects of the present study. First, this is one of a few studies that prospectively compared coronary plaque characteristics using IVUS/VH in patients with MACE versus those without MACE over a 12-month period. Secondly, in addition to a cross-sectional analysis at the MLA site, we also used a detailed, 3D quantitative characterization of each plaque within the region of the IVUS pullback, providing more insight into the overall features of those plaques.

The present study has five important findings. First, as expected, event rate associated with intermediate lesions was low; only 5 of 60 plaques (8.3 %) were responsible for MACE over a 12-month period. Secondly, FFR was similar in plaques with and without MACE. Thirdly, as previously reported in PROSPECT \[[@CR16]\] and VIVA \[[@CR20]\], lesions associated with MACE had significantly more plaque, as evidenced by higher plaque area at the MLA site and higher plaque burden in the entire plaque. Fourthly, plaque composition in MACE lesions was shifted toward less calcified and more non-calcified components, as evidenced by less dense calcium both at the MLA site as well as in the entire plaque. Finally, a unique and novel finding was the higher amount and percentage of fibrofatty tissue both at the MLA site as well as in the entire plaque. Importantly, all five MACE lesions were characterized as VH-TCFA compared to only 69 % of non-MACE plaques, although this was not statistically significant.

The progression of atherosclerosis follows a reasonably predictable course \[[@CR22]\] through some distinct phases and characteristic phenotypes and several features can be detected by IVUS/VH \[[@CR21], [@CR23]\]. Growth in coronary plaque size initially occurs in an outward fashion with preservation of the luminal size; this process is called "positive" remodeling and was initially described by Glagov \[[@CR24]\] and presents an excellent target for atherosclerosis imaging by IVUS/VH \[[@CR25]\]. This stage of positive remodeling is followed by continued phagocytosis by macrophages leading to development of a necrotic core and subsequent formation of TCFAs \[[@CR6], [@CR9]\]. While IVUS/VH is able to accurately detect and quantify necrotic core in human coronary arterial plaques \[[@CR21]\], its resolution is not high enough to measure the thickness of the fibrous cap; however, an IVUS/VH definition of TCFA has been devised and is referred to as VH-TCFA \[[@CR15], [@CR26]\] (Fig. [5](#Fig5){ref-type="fig"}). Ruptured TCFAs are thought to be one of the most important underlying causes of sudden cardiac death and ACSs \[[@CR6], [@CR8]\]. Calcification, which occurs as part of the healing process in large, positively remodeled plaques that undergo repeated, spontaneous intra-plaque hemorrhage without leading to ACS \[[@CR27]\], is also an easy target for IVUS/VH imaging \[[@CR28], [@CR29]\]. Finally, the latest stages of the atherosclerotic process are characterized by further calcification and fibrosis, severe luminal stenosis, and negative remodeling and can also be easily detected by IVUS/VH.

In the context of this atherosclerosis paradigm, our study showed that MACE lesions had similar lumen size and FFR compared to non-MACE lesions, while they were characterized by larger plaque burden with more non-calcified plaque, especially the fibrofatty kind, with significantly less calcium. Furthermore, all five of MACE lesions were characterized as VH-TCFA. Therefore, our study is consistent with histopathological studies of coronary atherosclerosis.

Our findings are also consistent with previous imaging studies and expand on those findings. With regards to event rates, a large meta-analysis by Nicholls et al. demonstrated that MACE rate associated with non-obstructive lesions, similar to our study, was approximately 11 % per year, similar to the 8.3 % found in our study \[[@CR30]\]. The results of the large, prospective PROSPECT study have been published showing an annualized event rate of 6.9 % in intermediate coronary lesions, similar to our study \[[@CR16]\].

It is not surprising that in the present study FFR was not different between groups since we only included intermediate lesions. It is well known that with the inclusion of the entire spectrum of intermediate-to-severe stenosis, FFR has significant prognostic value \[[@CR31]\].

Previous IVUS-based studies also showed that MACE lesions were associated with larger plaque burden and relatively preserved luminal size \[[@CR30]--[@CR32]\].

Results from PROSPECT, a large, prospective, landmark study using three-vessel IVUS/VH in approximately 700 patients with ACS followed for a median of 3.4 years, showed that MLA \< 4 mm^2^ \[hazard ratio (HR), 3.21, *p* = 0.001), plaque burden 70 % (HR, 5.03, *p* \< 0.001) or greater, and the presence of VH-TCFA (3.35, *p* \< 0.001) were independent predictors of MACE. Results from VIVA, an additional large prospective study using three-vessel IVUS/VH in 170 patients with stable angina and ACS followed for 1.9 years, demonstrated that MLA \< 4 mm^2^ (HR, 2.91, *p* = 0.036), plaque burden \> 70 % (HR, 7.48, *p* = 0.001), and VH-TCFA (HR, 8.16, *p* = 0.007) were associated with MACE; our findings are largely consistent with these findings \[[@CR16], [@CR20]\].

We also found that MACE lesions had more non-calcified plaque and less calcified components. This is consistent with histopathological findings, which showed that ACS lesions were associated with less calcification compared to stable lesions \[[@CR11], [@CR12]\]. These findings are also consistent with those by Yamagishi et al. \[[@CR32]\] and Sano et al. \[[@CR33]\], who also found more lipid-rich plaque and more echolucent plaque in culprit lesions, compared to non-culprit lesions.

One relatively unexpected, and previously unreported, finding in our study was the difference in fibrofatty tissue volume and percentage between MACE and non-MACE lesions, both at the MLA site, as well as in the entire plaque. Interestingly, in the multivariable analysis, this was the only feature that retained independent significance. Relatively little data is available with regards to fibrofatty tissue on IVUS/VH. Histopathologically, it probably represents slightly earlier-stage, lipid-rich plaques prior to the development of a necrotic core. The fact that our study was a lower-risk population compared to some of the previous studies described above, which mostly enrolled patients with ACS, while our study population was not an ACS population may be a potential explanation for this finding. Furthermore, it has been suggested that thrombi may be identified as fibrofatty tissue on IVUS/VH \[[@CR34]\]; however, careful review of our cases did not identify thrombus in these cases.

This study adds to the current literature on the predictive value of IVUS/VH for the prospective identification of potential lesions that may be associated with MACE in the future.

Limitations {#Sec17}
===========

There are several limitations to our study. Most importantly, it was a single-center study with a relatively low sample size. As it was described above, the primary endpoint of the overall study was the agreement between IVUS/VH and coronary CTA for percent atheroma volume, and sample size calculation was designed to fulfill that primary endpoint. Therefore, the study was not powered for the detection of MACE. Nevertheless, we did collect pre-specified MACE events in the study, all events were adjudicated by two cardiologists, and the statistical analysis revealed significant differences between MACE and non-MACE lesions, despite the low overall sample size. In addition, as a consequence of the lower number of patients in the MACE group, the multivariable analysis is limited. As a result, the data generated in this study should only be hypothesis generating. Secondly, the follow-up period of 12 months was relatively short, although this time-point is customary for the follow-up of MACE in large clinical trials. Thirdly, we only evaluated one vessel in each patient by IVUS/VH. Finally, we did not perform serial IVUS/VH imaging; it was only performed at baseline. Other modalities, such as coronary CTA, may be better positioned for serial imaging, as the dropout rate in serial IVUS studies is approximately 30--40 % \[[@CR35]\].

Conclusions {#Sec18}
===========

In conclusion, our study found that while major cardiovascular event rates were low due to non-flow-limiting, intermediate coronary arterial lesions, MACE lesions by IVUS/VH overall had larger plaque burden due to more non-calcified plaque components, mostly due to fibrofatty tissue and less calcified components. All lesions associated with MACE within a 12-month follow-up were characterized as VH-TCFA at baseline. Understanding the natural history of non-flow-limiting coronary arterial lesions will aid in designing pre-emptive strategies to combat vulnerable plaques, and such strategies will have to be tested in large-scale, multi-center clinical outcome trials.
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